Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2003

View Archived Issues

Activation of LXRs prevents development of atherosclerosis

Label extension approved for Cozaar

Emend approved by FDA for chemotherapy-induced nausea and vomiting

Novel tyrosine kinase inhibitors and their use reported by Merck

Florida State researchers prepare new antitumor paclitaxel derivatives

New antimalarial compounds designed by Japanese scientists

BMS researchers describe new inhibitors of MMPs, TACE and/or aggrecanase

Pfizer designs new PDE4 inhibitors

Lion Bioscience presents novel FXR modulators for lipid disorders and cancer

New monoamine receptor modulators covered by Sepracor patent

Novel antagonists of non-CB1/CB2 cannabinoid receptors with utility in septic shock

Merck identifies novel alpha2/alpha3-selective GABA-A receptor modulators

Vicuron and Novartis extend collaboration

InSite advances therapeutic programs

Titan focuses on four key programs

Telik initiates phase III ASSIST-1 trial of TLK-286 in ovarian cancer

Two HIV vaccine candidates used in combination show promise in monkeys

Completion of rasagiline phase III program

DCF-987 phase II trial on track

BioXell commences phase II trial of BXL-628

Abbott and Karo Bio identify novel new compound for type 2 diabetes

NaPro BioTherapeutics licenses peptide targeting technology from M.D. Anderson

Alfimeprase safe and well tolerated in phase I

Tumor suppressor gene polypeptides, compositions and methods of use available from NIH

NIH offers for licensing invention for optimizing cardiac contraction

Potent, orally active Lp-PLA2 inhibitor in clinical development for atherosclerosis

New revised guidelines on tuberculosis issued by the ATS, the U.S. CDC and the IDSA

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...